Advertisement

A missed protective drug–drug interaction of DPP-4 inhibitors and statins on myopathy risk

  • Oliver KussEmail author
  • Wolfgang Rathmann
Letter to the Editor

Notes

Compliance with ethical standards

Conflict of interest

Both authors declare that there are no competing interests.

References

  1. 1.
    Antonazzo IC, Poluzzi E, Forcesi E, Salvo F, Pariente A, Marchesini G, De Ponti F, Raschi E (2019) Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. Acta Diabetol.  https://doi.org/10.1007/s00592-019-01378-7 CrossRefPubMedGoogle Scholar
  2. 2.
    Thakrar BT, Grundschober SB, Doessegger L (2007) Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 64:489–495CrossRefGoogle Scholar
  3. 3.
    Ihle P, Dippel FW, Schubert I (2018) Statin-associated myopathy. Assessment of frequency based on data of all statutory health insurance funds in Germany. Pharmacol Res Perspect 6(3):e00404CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute for Biometrics and Epidemiology, German Diabetes CenterLeibniz Institute for Diabetes Research at Heinrich Heine University DüsseldorfDüsseldorfGermany
  2. 2.Institute of Medical Statistics, Medical FacultyHeinrich Heine University DüsseldorfDüsseldorfGermany
  3. 3.German Center for Diabetes Research (DZD)Neuherberg, MunichGermany

Personalised recommendations